George Goshua, MD, MSc is an Assistant Professor of Medicine (Hematology) in the Clinician-Scientist Track. He is a Yale-trained, board-certified internist and hematologist, with methodological training in risk and decision science from the Harvard T.H. Chan School of Public Health. Dr. Goshua is the PI of the first quantitative decision analytic modeling laboratory in hematology-oncology in the United States (Goshua Lab). His clinical expertise is in the care of adults with rare hematologic disorders, with a particular focus in immunohematology and thrombosis. His laboratory research employs quantitative decision analytic modeling methods to #1 fill gaps in clinical guidelines, #2 impact health resource allocation and/or #3 inform health policy decisions. This body of original science has been published in journals that include the Annals of Internal Medicine, Blood (inclusive of a #1 globally trending manuscript), The Lancet Haematology (the journal's #1 most cited original research), The Lancet Regional Health, Blood Advances, American Journal of Hematology (2021 AJH Young Investigator Award, 2022 AJH YIA Finalist), Science Immunology, Chest, and Clinical Infectious Diseases. Beyond research recognitions awarded by the leading hematology societies, Dr. Goshua's invited service at the interface of decision science and clinical medicine includes the 1. American Society of Hematology Patient Decision Aid Steering Group, 2. Institute for Clinical and Economic Review's Independent Appraisal Committee, and 3. Editorial Board at the Annals of Internal Medicine, with an expert focus in health economics.
Severe hemophilia A is a genetic disorder that prevents blood from clotting properly, posing a constant risk of dangerous bleeding episodes. Infants with severe hemophilia A (HA) are at risk of brain bleeds, which can lead to serious long-term brain damage. Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A.
05-Dec-2024 02:10:04 PM EST
Yale Cancer Center (YCC) researchers at Yale School of Medicine will present new research at the 66th annual American Society of Hematology (ASH) annual meeting in San Diego, Calif., December 7-10. Known as “the premier event in classical and malignant hematology”, the ASH meeting includes oral and poster presentations, as well as workshops and educational sessions for hematology professionals and advocates.
26-Nov-2024 02:15:29 PM EST
Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.
06-Dec-2023 12:05:29 PM EST